Breaking News

Share this information:

PFIZER Inc. disclosed on Monday that the company has began a mid- to late-stage study testing of an oral antiviral drug aimed to prevent COVID-19 infections among those who have been exposed in the virus. 

Together with its rivals, the US based Merck & Co Inc. and Swiss pharmaceutical Roche Holding AG, are in a race to produce the first antiviral pill to combat COVID-19. 

Pfizer stated that it would test the drug, PF-07321332, to 2,660 healthy adults aged 18 and above who live in the same household with a confirmed symptomatic patient. 

The PF-07321332 will undergo a trial with a low dose of ritonavir, a medication used to treat HIV infection. 

According to Merck and Ridgeback Biotherapeutics, they already enrolled patients in a late stage trial of the experimental drug molnupiravir for the prevention of COVID-19 earlier this month.

Pfizer, on the other hand, said that they already had began the trial earlier this month for the PF-07321332 to treat symptomatic adult patients who are not hospitalized. 


Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: